ISSN:
1432-1076
Keywords:
Bronchodilators
;
Infants
;
Bronchopulmonary disease
;
Baby-spacer device
;
Babyhaler
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract The response of salbutamol (Ventolin, Glaxo), topically administered from a metered dose inhaler (MDI) through a new baby-spacer-device (Babyhaler, Glaxo) was studied in 14 infants (8 wheezy infants, 3 infants with cystic fibrosis and 3 infants after respiratory distress syndrome), age 2.9–18.8 months. Changes in thoracic gas volume (TGV) as an estimate of pulmonary hyperinflation and changes in airway conductance (Gaw) as an estimate of bronchial obstruction were assessed by whole-body plethysmography. After baseline measurements, 1 puff of 100 μg salbutamol was given repeatedly at 5 min intervals until 600 μg have been inhaled and TGV and Gaw were measured after each inhalation at 5, 10, 15, 20, 25 and 30 min. Significant improvement in lung function was achieved in 57.1% of infants after 400 μg and in 92.9% of infants after 600 μg salbutamol. The study shows usefulness of bronchodilator treatment in infants with bronchopulmonary disease by a system with a MDI and baby-spacer-device. However a special dose-time relationship must be respected.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02073894
Permalink
